Catalent Pharma and CTC BIO to partner in South Korea

Monday, September 17, 2012 11:21 AM

Catalent Pharma Solutions, a Somerset, N.J.-based developer of solutions and drug delivery technology, and CTC Bio, a drug and service provider based in Seoul, South Korea, have entered into a collaboration to provide optimal solutions to South Korean pharmaceutical companies seeking to commercialize solid oral dose and controlled release products in the U.S. and Europe.

Combining CTC Bio’s position in the region with Catalent’s expertise in controlled release formulations, manufacturing network and broad experience in global product launches will provide South Korean companies with access to international markets.  

“South Korea is a highly innovative region, developing new products and effective pharmaceutical formulations,” said H.R. Jeon, CSO of CTC Bio. “This collaboration with Catalent provides South Korean pharmaceutical customers with better access to the leading provider of innovative controlled release drug delivery technologies and supply capabilities. Catalent's breadth of services and reputation for successful new product launches in international markets makes them an ideal partner for us and our clients/partners in South Korea.”

Share:          
CWWeekly

April 13

Quintiles-Quest Diagnostics joint venture latest in CRO-central lab deals, more could be on horizon

Biotech companies raise record amount of capital in Q1

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

April

PSI, INC Research, Chiltern best with sites
Strategic outsourcing prioritizing, improving site relationships

Regulatory compliance an increasing burden on sites
Increased staff time, materials, storage eroding site operating profit

Already a subscriber?
Log in to your digital subscription.

Purchase the March issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

March

Novo Nordisk, Takeda, Servier, Celgene among top sponsors
New gains seen from patient- and site-centric initiatives

Patient reported outcomes take center stage
FDA combining PROs, clinical outcomes in its approval decisions

Already a subscriber?
Log in to your digital subscription.

Purchase the February issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs